drugset
drugset / Trial / NCT00143247

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

NCT00143247 ↗

Phase 2 Terminated 173 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).

Timeline

Start
2003-03
Primary completion
2008-01
Completion
2008-01

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic — Inhaled

Indications

diabetes mellitus